
June 2 (Reuters) - Vera Therapeutics Inc VERA.O:
VERA THERAPEUTICS ANNOUNCES ATACICEPT ACHIEVED 46% PROTEINURIA REDUCTION IN ORIGIN PHASE 3 TRIAL IN ADULTS WITH IGA NEPHROPATHY
VERA THERAPEUTICS INC - TO SUBMIT BLA FOR ATACICEPT TO FDA IN 4Q 2025
VERA THERAPEUTICS INC - ATACICEPT SAFETY PROFILE FAVORABLE AND COMPARABLE TO PLACEBO
VERA THERAPEUTICS INC: PRIMARY ENDPOINT WAS MET IN ORIGIN PHASE 3 TRIAL OF ATACICEPT